Regorafenib Combined With PD-1 Inhibitor Therapy for Second-line Treatment of Hepatocellular Carcinoma
Status:
Recruiting
Trial end date:
2022-12-01
Target enrollment:
Participant gender:
Summary
This is a single arm, nonrandomized, single center clinical study to investigate the safety
and efficacy of regorafenib combined with PD-1 inhibitor therapy for second-line treatment of
hepatocellular carcinoma